Last reviewed · How we verify

NCT04044534

Intranasal Insulin for Posttraumatic Stress Disorder

Recruiting now Phase 2 Last updated 16 September 2025
What this trial tests

Phase 2 trial testing Intranasal insulin in PTSD in 20 participants. Currently enrolling.

Timeline
31 October 2024
Primary endpoint
31 May 2026
31 May 2026

Quick facts

Lead sponsorVA Connecticut Healthcare System
PhasePhase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposetreatment
Enrollment20
Start date31 October 2024
Primary completion31 May 2026
Estimated completion31 May 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

VA Connecticut Healthcare System — full company profile →

Who can join

Adults 21 to 65, any sex, with PTSD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate if intranasal insulin is effective in reducing PTSD symptoms.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Imaging of intranasal drug delivery to the brain.
    Veronesi MC, Alhamami M, Miedema SB, Yun Y, et al · · 2020 · cited 63× · PMID 32211216
  2. Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder.
    Singewald N, Sartori SB, Reif A, Holmes A. · · 2023 · cited 40× · PMID 36623804 · DOI 10.1016/j.neuropharm.2023.109418

Verify or expand the search:

Other trials of Intranasal insulin

Trials testing the same drug.

Other recruiting trials for PTSD

Currently open trials in the same condition.

Other VA Connecticut Healthcare System trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04044534.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing